Harvesting the power of the cell’s own protein degradation mechanisms in drug discovery
Posted 21st October 2020 by Joshua Sewell
Constant production of proteins in living cells is subject to strict quality and concentration control. The ubiquitin-protease system (UPS) is one of the systems responsible for degrading misfolded and damaged proteins. Also, short-lived regulatory proteins that control many critical cellular processes, including cell cycle progression, cell proliferation and differentiation, cell signalling and transcription are degraded by UPS.1
Reshaping drug discovery with deep learning and polypharmacology
Posted 23rd October 2019 by Joshua Sewell
Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.
Why drug designers will be at a disadvantage without AI
Posted 16th September 2019 by Liv Sewell
We spoke to John Griffin, CSO at Numerate, to find out how AI is changing drug discovery and development. Numerate is a drug design company applying cutting-edge AI to transform the process of small molecule drug design.
Integrating AI and HCI for drug discovery
Posted 1st October 2018 by Jane Williams
Bringing new therapeutics to patients is easier said than done due to the enormous intrinsic complexity behind being efficacious and safe.
Accelerating the Medicinal Chemistry Design Cycle
Posted 6th April 2018 by Jane Williams
MedChemNet and Future Medicinal Chemistry editors Jasmine Harris and Ben Walden interviewed Emma Parmee from Merck & Co at the Global Medicinal Chemistry and GPCR Summit.